Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes

  • J Med Chem. 2009 Oct 22;52(20):6201-4. doi: 10.1021/jm900951n.
Nicole C Goodwin  1 ,  Ross Mabon ,  Bryce A Harrison ,  Melanie K Shadoan ,  Zheng Y Almstead ,  Yiling Xie ,  Jason Healy ,  Lindsey M Buhring ,  Christopher M DaCosta ,  Jennifer Bardenhagen ,  Faika Mseeh ,  Qingyun Liu ,  Amr Nouraldeen ,  Alan G E Wilson ,  S David Kimball ,  David R Powell ,  David B Rawlins
Affiliations
  • 1. Department of Medicinal Chemistry, Lexicon Pharmaceuticals, 350 Carter Road, Princeton, New Jersey 08540, USA. [email protected]
PMID: 19785435 DOI: 10.1021/jm900951n
Abstract

The prevalence of diabetes throughout the world continues to increase and has become a major health issue. Recently there have been several reports of inhibitors directed toward the sodium-dependent glucose cotransporter 2 (SGLT2) as a method of maintaining glucose homeostasis in diabetic patients. Herein we report the discovery of the novel O-xyloside 7c that inhibits SGLT2 in vitro and urinary glucose reabsorption in vivo.